Greenwich LifeSciences (NASDAQ:GLSI) Upgraded by Wall Street Zen to Hold Rating

Key Points

• Greenwich LifeSciences (NASDAQ: GLSI) was upgraded by Wall Street Zen from a “sell” to a “hold” rating in a recent research report.
• The stock opened at $22.86 on Friday, giving the company a market capitalization of about $316.61 million; it has traded between $7.78 and $34.10 over the past year.
• Greenwich LifeSciences is a clinical-stage biotechnology company focused on immune modulators for cancer and autoimmune diseases, and institutional ownership remains relatively limited at 4.16%.

Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Saturday.

Greenwich LifeSciences Stock Performance

Shares of GLSI opened at $22.86 on Friday. The firm has a market capitalization of $316.61 million, a price-to-earnings ratio of -15.66 and a beta of 1.39. Greenwich LifeSciences has a one year low of $7.78 and a one year high of $34.10. The stock's fifty day moving average is $25.07 and its 200-day moving average is $19.92.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of GLSI. Bank of America Corp DE grew its holdings in Greenwich LifeSciences by 22.3% during the fourth quarter. Bank of America Corp DE now owns 7,262 shares of the company's stock worth $82,000 after acquiring an additional 1,322 shares during the period. Rhumbline Advisers grew its holdings in Greenwich LifeSciences by 48.7% during the first quarter. Rhumbline Advisers now owns 9,673 shares of the company's stock worth $92,000 after acquiring an additional 3,168 shares during the period. Wells Fargo & Company MN grew its holdings in Greenwich LifeSciences by 109.6% during the fourth quarter. Wells Fargo & Company MN now owns 7,845 shares of the company's stock worth $165,000 after acquiring an additional 4,102 shares during the period. Strs Ohio acquired a new position in Greenwich LifeSciences during the first quarter worth about $177,000. Finally, Jane Street Group LLC acquired a new position in Greenwich LifeSciences during the fourth quarter worth about $203,000. 4.16% of the stock is owned by institutional investors and hedge funds.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc NASDAQ: GLSI is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company's product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.